Paul R. Edick - 15 Nov 2021 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Role
Chairman & Chief Executive Officer, Director
Signature
/s/ Beth Hecht as Attorney-in-Fact
Issuer symbol
XERS
Transactions as of
15 Nov 2021
Net transactions value
+$45,664
Form type
4
Filing time
16 Nov 2021, 15:25:02 UTC
Previous filing
12 Nov 2021
Next filing
05 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XERS Common Stock Purchase $45,664 +20,000 +149% $2.28 33,430 15 Nov 2021 By: Paul R. Edick 2008 Revocable Trust u/d/t dated 6/25/2018 F1, F2
holding XERS Common Stock 808,064 15 Nov 2021 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.275 to $2.30, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F2 The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Remarks:

Chairman & Chief Executive Officer